- 12 September 2017 - 14 September 2017
- Malmömassan – Malmö Convention Center Mässgatan 6 215 32, Malmö
- 05 May 2017 - 07 May 2017
- Bologna Fair Centre
- Bologna, Italy
- 15 May 2017 - 18 May 2017
- National Exhibition and Convention Center
- Shanghai, China
- 28 June 2017 - 30 June 2017
- Tokyo Big Sight, Tokyo
- 28 June 2017 - 30 June 2017
- Tokyo Big Sight, Tokyo
Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden.
Epidemiologists conducting national precision medicine initiatives focused on gathering clinical research data on genetic variation among East and South Asian populations now have access to Thermo Fisher Scientific's Applied Biosystems Axiom Asia Precision Medicine Research Array.
AbbVie , a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors.
Spheryx, Inc. announced that the National Center for Advancing Translational Science (NCATS) of the NIH has awarded the company a Phase II SBIR grant for $1,500,000 over 2 years to support the modification of their proprietary Total Holographic Characterization® technology to meet the specific needs of the biologics pharmaceutical industry.
Viking Therapeutics, Inc , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.
Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA.
Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.
Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry announced an agreement with Nova Biomedical (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.
Contract development and manufacturing organisation (CDMO) Saneca Pharma has been granted a multiple dosage form approval for the manufacture and supply of solids, semi-solids and liquid finish dose products to Russia.
Manufacturers require high code accuracy and legibility from their Thermal Transfer Overprinters to improve production line efficiency and reduce overall costs.
With the recent increase in health consciousness globally, the concept of "farm to fork" has swept the world. As a result of this, the search for methods to reduce food loss and waste in the supply chain from the farm to the dining table, has becomea critical problem to solve; from the perspectives of both economics and environmental protection.
A Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with the installation of new automatic capsule filling capabilities at its EU-GMP approved plant in Pamplona, Spain.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers. If this data were liberated to the masses, we would venture into a world of endless possibilities where the search for new cures and treatments could be accelerated.
Valeant Pharmaceuticals International, Inc announced that certain affiliates of the Company have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited .
Medicure Inc , a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017.
Valeant Pharmaceuticals International, Inc. announced that its affiliate has completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon Pharmaceuticals LLC to the Sanpower Group, Co., Ltd. , for $819.9 million in cash.
Orphan genetic diseases have become an increasingly popular area for drug development through a variety of novel mechanistictherapeutic approaches.
Automation in its broadest sense has expanded from its original industrial manufacturing base to laboratories and businesses.
The deadlines for serialisation compliance in the EU and the U.S. are drawing closer. For many pharmaceutical companies, the journey towards implementing a full serialisation solution is well underway, but for others the complexity of the task means that there is still a lot to do.
Eisai Co., Ltd. announced that it has submitted applications to the US FDA and the EMA for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC).
More than one third (40 per cent) of pharmaceutical industry professionals are not confident that they will meet serialization deadlines in the US and Europe, according to new industry research.
BRITISH biotech business TopiVert has recently initiated clinical trials with two of its narrow spectrum kinase inhibitor (NSKI) drug candidates following support from Onyx Scientific.